Aprea director granted RSUs and stock options
Aprea Therapeutics director John B. Henneman III received new equity awards.
Rhea-AI Filing Summary
Aprea Therapeutics director John B. Henneman III received new equity awards. He was granted 3,135 restricted stock units on June 16, 2026, which will vest and settle in common stock on June 16, 2027, if he remains on the board. He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. Following these awards, he directly holds 13,364 shares of common stock, while the options and restricted stock units represent additional potential future ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,690 shares
Grant/Award
2 txns
Insider
HENNEMAN JOHN B III
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 12,555 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,135 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 12,555 contracts (Direct);
Common Stock — 13,364 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- F2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Key Figures
Restricted stock units granted: 3,135 units
Stock options granted: 12,555 options
Option exercise price: $0.7293 per share
+3 more
6 metrics
Restricted stock units granted
3,135 units
Granted June 16, 2026; vesting June 16, 2027
Stock options granted
12,555 options
Granted June 16, 2026; vesting June 16, 2027
Option exercise price
$0.7293 per share
Stock Options (Right to Buy) for Aprea common stock
Option expiration date
June 16, 2036
Expiration of granted stock options
Shares held after transaction
13,364 shares
Common stock directly owned after grants
Underlying option shares
12,555 shares
Common stock underlying the stock options
Key Terms
restricted stock units, Stock Options (Right to Buy, vesting, board of directors
4 terms
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy financial
"Stock Options (Right to Buy) with an exercise price of 0.7293 and expiration date of 2036-06-16"
vesting financial
"which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
board of directors financial
"subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aprea Therapeutics (APRE) disclose in this Form 4 filing?
Aprea Therapeutics disclosed equity awards to director John B. Henneman III. He received 3,135 restricted stock units and stock options for 12,555 shares, both granted on June 16, 2026, subject to future vesting conditions tied to continued board service.
What stock options did the Aprea Therapeutics director receive in this Form 4?
The director received options covering 12,555 shares of Aprea Therapeutics common stock. The options have an exercise price of $0.7293 per share, vest in full on June 16, 2027, and are scheduled to expire on June 16, 2036, if not exercised earlier.
When do the Aprea Therapeutics restricted stock units and options vest?
Both the 3,135 restricted stock units and the 12,555 stock options granted to the director vest on June 16, 2027. Vesting requires his continued service on Aprea Therapeutics’ board of directors through that date, with potential acceleration only under specified conditions in the award terms.
Are the Aprea Therapeutics equity awards to the director market purchases or compensation grants?
The Form 4 shows compensation-related grants to the director, not open-market purchases. Both the restricted stock units and stock options were awarded at no cash cost per share on grant, reflecting equity compensation tied to his ongoing board service with Aprea Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
